Evidence for Effectiveness

Similar documents
Evidence Standards and AI

2. Evidence themes and their importance along the development path

IoT in Health and Social Care

The NHS England Assurance Framework: national report for consultation Chief Officer, Barnet Clinical Commissioning Group

ABHI Response to the Kennedy short study on Valuing Innovation

Digital Health Strategy

CCG Improvement and Assessment Framework 2016/17. Briefing Document

Doing, supporting and using public health research. The Public Health England strategy for research, development and innovation

Portsmouth CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only

Co-Design. Dr Louise Moody Coventry University Devices 4 Dignity, UK

Enfield CCG. CCG 360 o stakeholder survey 2014 Summary report. Version 1 Internal Use Only Version 1 Internal Use Only

Sutton CCG. CCG 360 o stakeholder survey 2014 Summary report. Version 1 Internal Use Only Version 1 Internal Use Only

West Norfolk CCG. CCG 360 o stakeholder survey 2014 Main report. Version 1 Internal Use Only Version 7 Internal Use Only

Software as a Medical Device (SaMD)

Enfield CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only

Oxfordshire CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only

Southern Derbyshire CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only

South Devon and Torbay CCG. CCG 360 o stakeholder survey 2015 Main report Version 1 Internal Use Only

Sutton CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only

Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation

Innovation & health connected. Business plan summary

December Eucomed HTA Position Paper UK support from ABHI

Towards a Consumer-Driven Energy System

A review of the role and costs of clinical commissioning groups

3. Title NHSE & Ipsos Mori CCG 360 Stakeholder Survey

Human factors and design in future health care

NHS and Social Care Innovation and Diffusion Challenges

The EFPIA Perspective on the GDPR. Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference , Helsinki

Horizon 2020 ICT Robotics Work Programme (draft - Publication: 20 October 2015)

MRC Health and Biomedical Informatics Research Strategy

Navigating the Healthcare Innovation Cycle

GPC update on co-commissioning of primary care: Important Guidance for CCG member practices and LMCs

Compliance for Eucomed: The Medical Technology Industry s s Perspective

SHTG primary submission process

Engaging UK Climate Service Providers a series of workshops in November 2014

Stage 2: eligibility screening. Stage 3: prioritisation. Stage 4: selection

Issues in Emerging Health Technologies Bulletin Process

NIHR ROADSHOW FOR MEDTECH SMES

DEPARTMENT OF COMMUNICATIONS. No April 2013 MINISTER OF COMMUNICATIONS OUTLINE OF THE ICT POLICY REVIEW PROCESS, 2013

EMA experience with the review of digital technology proposals in medicine development programmes

Technology and Innovation in the NHS Highlands and Islands Enterprise

Our position. ICDPPC declaration on ethics and data protection in artificial intelligence

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

Digitisation Plan

Centre for Healthcare Technologies

The Industrial Strategy Challenge Fund

13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer

INNOVATION, HEALTH AND WEALTH ACCELERATING THE ADOPTION AND DIFFUSION IN THE NHS. MELANIE OGDEN DEPUTY DIRECTOR OF INNOVATION October 2013

Safety related product corrective action

Parkinson s World A transformational project by The Cure Parkinson s Trust

NHS Next Stage Review: Innovation

NHS HMR CCG and NHS England Primary Care Joint Commissioning Committee 2015/16

GOVERNING BODY MEETING in Public 25 April 2018 Agenda Item 3.2

Copyright: Conference website: Date deposited:

EGIDA Project The EGIDA Methodology P. Mazzetti (CNR-IIA) Istanbul, Turkey November, 2011

e-care Living Lab - 5 avenue du Grand Sablon La Tronche - FRANCE Tel: +33 (0)

The Information Commissioner s response to the Draft AI Ethics Guidelines of the High-Level Expert Group on Artificial Intelligence

LIVING LAB OF GLOBAL CHANGE RESEARCH

Dr George Gillespie. CEO HORIBA MIRA Ltd. Sponsors

25 th Workshop of the EURORDIS Round Table of Companies (ERTC)

Horizon Scanning. Why & how to launch it in Lithuania? Prof. Dr. Rafael Popper

Health & Social Care Industrial Innovation

Accountable Officer Report

Hints & Tips: NIHR Evaluation Trials & Studies Coordinating Centre (NETSCC) Funding Opportunities for Northern Ireland

Digital Health and Introducing Innovative Technologies in the NHS

Supporting Innovation through Regulation and Science

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)

Scottish Health and Life Sciences Innovation Workshop. The Industrial Strategy Challenge Fund

Medical Education Activities

SMART PLACES WHAT. WHY. HOW.

Herts Valleys Clinical Commissioning Group. Review of NHS Herts Valleys CCG Constitution

The British Food Plan

3b. Definition of Readiness: Update on Readiness Package and FCPF/UN-REDD Collaboration

Health Innovation Manchester

AI in Europe How could the EC help European society and economy to make the best of this revolution?

Health Innovations in Horizon 2020: the framework programme for research and innovation ( )

NIHR / Wellcome Trust King s Clinical Research Facility. Guidance for Investigators

Human Rights Risk Tool for Seafood. Helen Duggan, Head of Responsible Sourcing, Seafish

Title: care.data Pathfinder Stage CCG Recruitment and Selection Process

Innovationen gemeinsam entwickeln und umsetzen

Consultancy on Technological Foresight

Implementation of Systems Medicine across Europe

Research Development Request - Profile Template. European Commission

The Potential Social and Economic Value of Innovation Procurement

Maturity Model for Integrated Care Dr Andrea Pavlickova NHS 24, Scotland

WHO Regulatory Systems Strengthening Program

Helping your business grow in the UK health system

Enabling ICT for. development

Twenty-Thirty Health care Scenarios - exploring potential changes in health care in England over the next 20 years

A Roadmap for Connected & Autonomous Vehicles. David Skipp Ford Motor Company

Gender pay gap reporting tight for time

ANZPAA National Institute of Forensic Science BUSINESS PLAN

UK High-Field NMR Funding and the UKRI Infrastructure Roadmap

Science for Policy. Impact of Social Sciences & Humanities. David Mair (chair) Antti Pelkonen Mihiri Seneviratne. Gemyse 1,

National Workshop on Responsible Research & Innovation in Australia 7 February 2017, Canberra

Andalusian Agency for Health Technology Assessment (AETSA)

"I and my Ministerial colleagues recognise the imperative and opportunity to see more co-production in the design and delivery of public services.

Dr Andrea Pavlickova NHS 24, Scotland

WG/STAIR. Knut Blind, STAIR Chairman

Innovative Approaches in Collaborative Planning

Transcription:

Evidence for Effectiveness Developing a standards framework for digital health innovations Digitally empowering people to manage their health and care October 2018

The issue NHS England programmes Apps library - DAQs ITP/ITT Digital Diabetes programme Test Beds Innovation Landscape Review Literature review, workshops, interviews Clear requirement for consistent evidence standards Cycle of Pilots Little at scale implementation Emerging trust in digital health 2

The Problem The Goals How to demonstrate the impact of a digital health tool with appropriate evidence. Manufacturers are not clear what effectiveness and economic evidence they need to produce Commissioners are unclear what effectiveness and economic evidence they should be looking for A cycle of pilots and trials in the innovation space with little focus at scale implementation of such tools and value for money to the health and social care system. A trusted and respected source of advice on what evidence to produce; allowing innovators to produce better evidence, faster and more cost-effective, and in turn allow the NHS to commission, deploy and scale clinically and cost-effective digital health tools that meet demand. Related standards on how to produce evidence of effectiveness, economic impact and compliance with other standards. 3

Project Scope Type of digital health tools In Scope Digital health tools that are patient, citizen or clinician facing This will include mobile and web apps, wearables, digital therapeutics, VR/AR technology Apps that enable innovative value propositions and use of medical devices and diagnostics. Out of Scope Health IT systems True AI based digital tools the subject of a targeted initiative Conventional medical software required for the standard operation of a medical device or diagnostic. Type of evidence End goal of the advice Objective of the work Evidence to demonstrate clinical effectiveness Evidence to demonstrate behaviour change Evidence to demonstrate value for money and economic benefit To be commissioned or recommended by the NHS or its related health and care systems (e.g community clinics) and including social care Where applicable, to turn this advice into standards for future assessment to serve as a benchmark reference for innovators and commissioners To make easily accessible advice on how to generate evidence and why it matters Evidence of clinical safety Evidence that support security, data processing, technical stability Overseas market, lifestyle and wellbeing market To design the overall assessment framework for digital tools e.g. who will assess effectiveness and value for money in the system and when To review commissioning frameworks To design or build better infrastructure for 4 digital health research (NIHR)

Project Scope - what the project will and will not deliver Supporting evidence of effectiveness and economic impact Informing the assessment framework and process Evaluating individual tools 5

Project Milestones for developing Economic Standards July 18 Setting up project team and confirming scope of project Identify existing classification economic evaluation frameworks and establishing links with key stakeholders August 18 Developing a shared view of the conceptual approach to the economic standards. Sept 18 Host workshops with commissioners and innovators and develop content for digital tool Sept 18 Internal workshops with key advisors and project team Continue testing framework using and develop case studies that illustrate levels of evidence in the framework Oct - Nov 18 Workshops with wider set of stakeholders, innovators, academics, commissioners, ALBs, other key groups Dec - Jan 19 Development and launch of the support tool and standards Confirm arrangements for longer term maintenance 6

THE WIDER issue: innovation landscape review

A CODE OF CONDUCT principles and guidelines https://www.gov.uk/government/publications/code-of-conduct-for-data-driven-health-and-care-technology Real world feedback loop based on connected informative data sets 1 Idea 2 Standards 3 Evidence 4 Evaluation 5 Payment 6 Adoption Idea generation Does it meet the Standards? Evidence generation to show effectiveness Evaluation of ideas Payment and Commissioning Adoption by end users IDEA Code of Conduct For DHIs and Intelligent Algorithms ADOPTION, REGULATION AND EVIDENCE Digital Transformation Innovation landscape Review, Data led Policy, Value of Data HTA / Regulation / DAQs Commissioning, commercial and uptake WHAT THE CODE OF CONDUCT OFFERS 1. A clear set of principles and behaviours that creates a transparent and accountable environment for the development and deployment of trusted digital health innovations and intelligent algorithms within health and care. 2. Enable industry, academia, commissioners and individuals to easily identify the principles and guidelines of developing safe and effective products for the NHS. 3. Create a trusted set of products and innovations and a novel environment in health and care whereby we learn to base our policies on real world data and evidence thereby creating a unique framework to inform regulation. 8

Initial code of conduct for data-driven technologies Principle 9: Show evidence of effectiveness for the intended use You should provide evidence of how effective your product or innovation is for its intended use. If you are unable to show evidence, you should draw a plan that addresses the minimum required level of evidence given the functions performed by your technology...when building or developing the technology, consider what function the product delivers, and this will guide what sort of evidence generation plan should be put in place. The standards will also help the intended evaluation body review the package of evidence provided to them and help them outline gaps in the information they received from innovators Give feedback: https://www.gov.uk/government/publications/code-of-conduct-for-datadriven-health-and-care-technology 9

Who is involved? Project strategy & oversight Framework & Content Lead Comms & Integration Lead Evaluation Lead Innovation Lead AHSNs Lead Indra Joshi, NHS England Alexia Tonnel, Mark Salmon NICE Neelam Patel, MedCity Felix Greaves PHE Sam Roberts NHS England Axel Heitmeuller ICP, DH.L Executive Project Sponsors: Juliet Bauer, Chief Digital Officer, NHS England Simon Eccles, Chief Clinical Information Officer for Health and Care Gillian Leng Deputy Chief Executive, NICE www.medcityhq.com/evidence-for-effectiveness/ 10

The framework in outline Standards for clinical effectiveness evidence - based on functional classification Standards for economic effectiveness evidence - based on budget impact Educational/signposting resources, Case studies 11

DRAFT Clinical effectiveness standards Functional classification Evidence standards 12

Tier 2 evidence requirements DHTs that provide information, simple monitoring or communication functions only Evidence categories Must have Minimum evidence standard Could have Best practice standard Technical standards The DHT must have passed assessment using the NHS Digital DAQ tool n/a Content Be able to demonstrate that the information contained in the DHT is valid (aligned to best available sources e.g. NICE guidance, relevant professional organisations or reputable patient organisations, and appropriate for the target population), accurate up to date Evidence of a documented information review and update cycle during the lifetime of the DHT Evidence of endorsement, accreditation or recommendation by NICE, NHSE, relevant professional organisation or reputable patient organisation Evidence that the information content has been validated though independent accreditation/certification such as The Information Standard or HONcode certification Clinical engagement in the design process Be able to demonstrate that there was relevant clinical input in the design, development and testing of the DHT Relevance Evidence to demonstrate that the information contained in the DHT is relevant to the UK health and care system Evidence to demonstrate the DHT has been successfully piloted in the UK health and social care system Ongoing data collection n/a Commitment to collect and report to commissioners on usage and outcomes (using non-patient identifiable information) to show ongoing value 13

Economic Impact Standards Concept Budget impact of the DHT* to health and social care sector Economic evidence standards *DHT = Digital Health Tool 14

Conceptual framework Calculate the budget impact of the DHT* Classify the budget impact (England) of the DHT into one of four categories Economic evidence standards described for each budget impact category * Using publicly-available tool which is part of the framework 15

Budget impact categories Budget impact category* Annual net cost for England s Health and Social Care System Cost saving Less than 0 Cost neutral Less than 1 million Low cost Between 1 million and 15 million High cost Greater than 15 million *Categories based on existing NICE resource impact categories for England. Assign budget impact category based on the maximum annual net cost. 16

Economic evidence standards National budget impact category Cost saving Economic evidence standard for individual DHTs Output(s) Cost neutral Budget impact calculation Budget impact figure ( ) Low cost Budget impact and cost consequence analysis Budget impact, costs and consequences (such as health and other related outcomes) in natural units High cost Budget impact and cost effectiveness analysis Budget impact, costs and health outcomes summarised in a single nonmonetary measure e.g. QALY to provide an incremental costeffectiveness ratio (ICER) 17

Early Adoption Feedback, concerns? Ideas on adopting framework into programmes Feedback and Iteration 18